Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | NOS1 | P29475 | 1/20 | 0.60 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927388 | 0.93 | KMT2A (0.71) | TBXAS1ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL3581172 | 0.83 | ALDH1A1 (0.85) | TBXAS1ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL12382 | 0.83 | KMT2A (0.87) | TBXAS1ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL9451380 | 0.83 | TBXAS1 (0.68) | TBXAS1ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL76839 | 0.82 | KDM4E (0.72) | TBXAS1ALDH1A1KDM4EKMT2ANOS1 | |
| SCHEMBL10370478 | 0.82 | TBXAS1 (1.00) | TBXAS1ALDH1A1KDM4EKMT2ANOS1 | |
| Hydrochloric Acid SCHEMBL9996050 | 0.80 | TBXAS1 (0.97) | TBXAS1ALDH1A1KDM4EKMT2ANOS1 | |
| SCHEMBL7468628 | 0.80 | TBXAS1 (0.80) | TBXAS1ALDH1A1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL25344191 | 0.80 | TBXAS1 (0.64) | TBXAS1ALDH1A1KDM4EKMT2ANPSR1 | |
| SCHEMBL11977009 | 0.80 | TBXAS1 (0.63) | TBXAS1ALDH1A1KDM4EKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | disclosed |
| EP-2357182-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7956053-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2011-06-07 | — | — | US | disclosed |
| US-20090286821-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2009-11-19 | — | — | US | disclosed |
| EP-2100891-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-7569566-B2 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2008-08-07 | — | — | US | disclosed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0233461-B1 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 1996-03-20 | — | — | EP | disclosed |
| US-4876252-A | ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN | AMERICAN CYANAMID COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4788195-A | TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0233461-A2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID COMPANY (US) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | TBXAS1 1173/4885ALDH1A1 3475/4885KDM4E 519/4885 |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | TBXAS1 1173/4885ALDH1A1 3475/4885KDM4E 519/4885 |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | TBXAS1 1173/4885ALDH1A1 3475/4885KDM4E 519/4885 |
| US-20090286821-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | TBXAS1 1173/4885ALDH1A1 3475/4885KDM4E 519/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | TBXAS1 1176/4885ALDH1A1 2503/4885KDM4E 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.